Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2009-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00835640
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2009-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 60
- Registration Number
- NCT00835276
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2009-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00834990
- Locations
- 🇺🇸
PRACS Institute Ltd., Fargo, North Dakota, United States
Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Amlodipine-benazepril 10 mg-20 mg capsules
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2009-08-18
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 48
- Registration Number
- NCT00834977
- Locations
- 🇨🇦
Anapharm Inc., Montreal, Quebec, Canada
🇨🇦SFBC Anapharm, Sainte-Foy, Quebec, Canada
Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2009-07-09
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 140
- Registration Number
- NCT00835406
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT00835263
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
Leflunomide 20 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ARAVA™ 20 mg Tablets
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 84
- Registration Number
- NCT00834418
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: UNIRETIC® 15/25 mg tablets
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 60
- Registration Number
- NCT00835042
- Locations
- 🇺🇸
Bioassay Laboratory, Inc., Houston, Texas, United States
🇺🇸Gateway Medical Research, Inc., Saint Charles, Missouri, United States
Metformin ER 750 mg Tablets, Fed
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT00834613
- Locations
- 🇨🇦
Biovail Contract Research, Toronto, Ontario, Canada
Glimepiride 4 mg Tablets Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT00835172
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States